SCHEMBL6790664

SCHEMBL6790664

O=C(c1ccc([N+](=O)[O-])cc1)C(O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.65
CES2 O00748 2/20 0.65
LMNA P02545 2/20 0.65
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPK1 P28482 2/20 0.54
POLB P06746 1/20 0.54
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
MAPT P10636 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
SRD5A2 P31213 1/20 0.50
CYP1B1 Q16678 1/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
HSP90AA1 P07900 1/20 0.49
OPRK1 P41145 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL28889042 0.98 CES1 (0.62) CES1CES2LMNAALDH1A1KDM4E
Acetic Acid SCHEMBL11298094 0.95 CES1 (0.59) CES1CES2LMNAALDH1A1KDM4E
SCHEMBL6790659 0.93 CES1 (0.65) CES1CES2LMNAALDH1A1KDM4E
SCHEMBL30692971 0.91 MEN1 (0.58) CES1CES2LMNAALDH1A1KDM4E
SCHEMBL15695553 0.82 CES1 (0.57) CES1CES2ALDH1A1TDP1MAPK1
SCHEMBL11754936 0.82 CES1 (0.57) CES1CES2LMNAALDH1A1TDP1
SCHEMBL29291313 0.81 CES1 (0.53) CES1CES2LMNAALDH1A1TDP1
Benzoin SCHEMBL145 0.80 CES2 (1.00) CES1CES2LMNAALDH1A1KDM4E
Benzoin SCHEMBL2025536 0.80 CES2 (1.00) CES1CES2LMNAALDH1A1KDM4E
Benzoin SCHEMBL901258 0.80 CES2 (1.00) CES1CES2LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105884833-B Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl 江南大学 2020-05-08 CN claimed
CN-105884833-B Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl 江南大学 2020-05-08 CN disclosed
US-20040138228-A1 Novel compounds with analgesic effect ASTRAZENECA CANADA INC. 2004-07-15 US disclosed
EP-1408037-A1 Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect AstraZeneca AB (SE) 2004-04-14 EP disclosed
US-6680321-B1 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS ASTRAZENECA CANADA, INC. (CA) 2004-01-20 US disclosed
US-6130222-A Compounds with analgesic effect ASTRA PHARMA INC. (CA) 2000-10-10 US disclosed
EP-0915855-A1 NOVEL COMPOUNDS WITH ANALGESIC EFFECT Astra Pharma Inc. (CA) 1999-05-19 EP disclosed
WO-1997023466-A1 NOVEL COMPOUNDS WITH ANALGESIC EFFECT ASTRA PHARMA INC. (CA) 1997-07-03 WO disclosed
WO-1992013897-A1 AN ANTI-CRUST DECOLORIZED MATERIAL FOR THE POLYMERIZATION OF THE CHLORINATED OLEFINIC MONOMERS C.I.R.S. COMPAGNIA ITALIANA RICERCA E SVILUPPO S.R.L. (IT) 1992-08-20 WO disclosed
EP-0498142-A1 An anti-crust decolorized material for the polymerization of the chlorinated olefinic monomers C.I.R.S. COMPAGNIA ITALIANA RICERCA E SVILUPPO S.R.L. (IT) 1992-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138228-A1 Novel compounds with analgesic effect OPRL1, OPRK1, OPRM1 CES1 1582/4885CES2 2005/4885LMNA 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.